Emerging Paradigms in the Management of

Crohn’s Disease

Click here to
Register Now

Or Call Us Toll-Free At 855-276-6855

Activity Overview

To be eligible for documentation of credit for this live event, participants must attend the full activity and submit a completed evaluation form. All individuals who participated in the activity must complete and submit the evaluation form—to the on-site representative or by mail or fax within 2 weeks after the date of activity—to receive documentation of credit. Documentation of credit will be emailed within 8 weeks.

For questions regarding this educational activity please call 855-276-6855.

There is no fee associated with this activity.

Learning Objectives

After completing this activity, participants should be able to:

  • Risk stratify patients with moderate to severe Crohn’s disease for prognosis based on disease and patient characteristics
  • Select appropriate therapeutic options for patients with moderate to severe Crohn’s disease, considering risk/benefit profiles of each therapy
  • Choose early intervention with biologic agents for the induction and maintenance of clinical remission in appropriate patients with moderate to severe Crohn’s disease
  • Summarize the various indices used to determine treatment success in Crohn’s disease
  • Describe the evidence for using symptom-based and endoscopic treatment end points in Crohn’s disease


David G. Binion, MD

Professor of Medicine, Clinical and Translational Science

Co-Director, Inflammatory Bowel Disease Center

Director, Translational Inflammatory Bowel Disease Research

Director, Nutrition Support Service

Division of Gastroenterology, Hepatology and Nutrition

Department of Medicine

University of Pittsburgh School of Medicine

Pittsburgh, Pennsylvania

Raymond K. Cross, Jr., MD

Associate Professor of Medicine

Director, Inflammatory Bowel Disease Program at the University of Maryland School of Medicine

Co-Director of the Digestive Health Center at The University of Maryland Medical Center Baltimore, Maryland

Intended Learners

This activity is designed for gastroenterologists, primary care physicians, and healthcare providers who actively treat patients with Crohn’s disease.

Activity Locations & Schedule

6:30 pm - 7:00 pm
7:00 pm - 8:15 pm
Interactive Educational Session
Fee: There is no fee for this activity


North American Center for Continuing Medical Education (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

NACCME designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This continuing nursing education activity awards 1.25 contact hours.

Provider approved by the California Board of Registered Nursing, Provider Number 13255 for 1.25 contact hours.

ADA Statement
North America Center for Continuing Medical Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.

Independent Clinical Reviewer: David Greenwald, MD, Director of Endoscopy at the Henry Janowitz Division of Gastroenterology in the Samuel Bronfman Department of Medicine at The Mount Sinai Hospital, New York, New York.

Nurse Planner: Susie Seaman, NP, Sharp Rees-Stealy Wound Clinic, San Diego, California.

Planning Committee

The planning committee comprises David G. Binion, MD, Raymond K. Cross, Jr., MD, David Greenwald, MD, and Susie Seaman, NP; and Stephen Chavez, Kristin Ciszeski, Mary Johnson, Michael Kearney, Laura Parise, Randy Robbin, and John Savage, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Binion: Consultant—AbbVie, Cubist, Janssen, UCB Pharma, Salix; Investigator-initiated studies—Cubist, Janssen

Dr. Cross: Consultant—Abbvie, Takeda; Advisory Board—Janssen; Grant Support—Abbvie, Janssen, Shire, Takeda

Ms. Seaman: Scientific Advisor—Smith & Nephew, Molnlycke; Promotional Speakers’ Bureau—Smith & Nephew.

Mr. Chavez, Ms. Ciszeski, Ms. Johnson, Mr. Kearney, Ms. Parise, Mr. Robbin, and Mr. Savage have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty have disclosed no off label/unapproved uses of drugs and/or devices will be discussed in the presentations.

Copyright © 2015 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.

Grantor Support

Supported by an educational grant from AbbVie.